News

Allumiqs is strengthening its customer solutions with capabilities in detecting and quantifying proteins at unprecedented levels of sensitivity and accuracy.

Jennifer brings extensive knowledge and business development experience that will help drive innovation and increase both scientific and commercial collaborations with our customers and partners.

Allumiqs is excited to announce a new strategic partnership with The Research Institute of McGill University Health Centre (The Institute), a world-renowned biomedical and healthcare…

Halifax, Nova Scotia, September 16, 2024 – Allumiqs, a tech-enabled multiomics contract research organization (CRO), today announced the appointment of Derek Gooderham to its Board…

Allumiqs announced today that it is now a member of the biocrates Certified Laboratory Program, becoming the only Contract Research Organization (CRO) in North America…

We’re excited to once again connect with our mass spectrometry community at ASMS 2024, June 2-6 in sunny Anaheim, CA.

Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines. 

PhenoSwitch Bioscience is now Allumiqs. For the past year we have been operating as PhenoSwitch Bioscience – A Division of Allumiqs.  We are excited to…